Coherus Bio (CHRS) Stock Price, Quote & News

Company Profile

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investi...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 649 3530

Website: www.coherus.com

Address:

333 Twin Dolphin Drive, Suite 600, Redwood City, United States

Jack_Nicholson_Truth Apr. 24 at 9:29 PM

$CHRS another scam artist. Tell us more 30 years experience scammer. You have like one post every 6 months and clearly a scam account. Your choices are horrible so stop spreading your fud

0 · Reply

bioinsights Apr. 24 at 5:43 PM

$CHRS Full disclosure I am long 50K shares. Additionally I have 30 years in Biotech development in IO and fair balance is key. The MOA statement is mechanistic positioning, not proven clinical differentiation. Best-case clinical interpretation: Toripalimab may work in a broader patient population (less PD-L1 dependence) and drive somewhat stronger or more durable responses. Most likely reality (based on PD-1 class experience): Differences vs Pembrolizumab are incremental. Clinical outcomes will be driven more by: Tumor type, combination strategy (chemo, IO, targeted agents) and line of therapy. Clinical bottom line. Single-agent reality (class-wide): Most PD-1 inhibitors—including Toripalimab and Pembrolizumab—cluster around ~15–30% ORR in most solid tumors. Higher only in highly immunogenic settings. For toripalimab no clear evidence of meaningfully higher single-agent response rates. Mechanistic advantages (binding, agonism) have not translated into step-function clinical gains.

2 · Reply

Grandgustav Apr. 24 at 2:38 PM

$CHRS

0 · Reply

cdlawton07 Apr. 24 at 12:43 PM

$CHRS @bioinsights you shorting CHRS or something? Binding the FG loop can cause the cell to internalize the PD-1 receptor (the cell retracts the receptor from the surface and internalizes it). This is different than Keytruda binding to the receptor to simply block it. "Overall, our study demonstrates that toripalimab is differentiated from pembrolizumab in terms of stronger PD-1 binding, more potent in-vitro T cell activation and lower agonistic potential. These characteristics of toripalimab present it as a next generation PD-1 checkpoint inhibitor with potential for favorable clinical outcomes in treating cancer patients irrespective of their PD-L1 status." https://aacrjournals.org/mct/article/22/12_Supplement/C069/730343/Abstract-C069-Toripalimab-an-anti-PD-1-antibody But go ahead and keep trying to spread your disinformation.

0 · Reply

bioinsights Apr. 24 at 12:23 PM

$CHRS “10-fold more binding” = 10× tighter PD-1 affinity, but in the PD-1 class, it is rarely clinically meaningful on its own because current drugs already operate at or near maximal receptor occupancy.Most PD-1 drugs already achieve >90–95% receptor occupancy at standard doses Once saturated, more affinity ≠ more clinical effect. Where it can matter? Lower dose potential (if occupancy achieved at lower exposure). Competitive differentiation in crowded IO space (more marketing than biology in many cases). Edge cases: low antigen density or high PD-L1 expression tumors

0 · Reply

calibran_de Apr. 23 at 8:16 PM

$CHRS https://www.tipranks.com/news/blurbs/oppenheimer-reaffirms-their-buy-rating-on-coherus-biosciences-chrs-blurbs-news?utm_source=edition.cnn.com&utm_medium=referral

0 · Reply

BigDaddyCapital Apr. 23 at 7:35 PM

$CHRS whether you like this or not it is partially true. Which is why sp has been like a zombie company

1 · Reply

AlbertoBurgio Apr. 23 at 6:59 PM

$CHRS thank you for posting, I was waiting for the Samishere pattern to form. Now the signal is on.

1 · Reply

Samishere Apr. 23 at 6:20 PM

$CHRS Yep Yep ..and Yep!

1 · Reply

cdlawton07 Apr. 23 at 5:25 PM

$CHRS What are you on about? No one is saying that CHRS can immediately apply for FDA approval in Loqtorzi indications using the China data without U.S trials. "Small differences in MOA do not matter." You consider Loqtorzi being able to treat patients and produce results that Keytruda is unable to replicate "not mattering"? Won't be paying your posts any mind going forward if thats the case.

0 · Reply

Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

Mar 2, 2026, 9:30 AM EST - 7 weeks ago

Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

Feb 23, 2026, 9:30 AM EST - 2 months ago

Coherus Oncology to Participate in Upcoming Investor Conferences

Feb 17, 2026, 4:11 PM EST - 2 months ago

Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock

Feb 12, 2026, 9:18 PM EST - 2 months ago

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

Jan 6, 2026, 9:30 AM EST - 3 months ago

Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 9:30 AM EST - 3 months ago

Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)

Dec 8, 2025, 8:30 AM EST - 4 months ago

Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

Nov 7, 2025, 9:00 AM EST - 6 months ago

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

Nov 6, 2025, 4:14 PM EST - 6 months ago

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 1:54 PM EST - 6 months ago

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

Oct 30, 2025, 8:30 AM EDT - 6 months ago

Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 10, 2025, 4:32 AM EDT - 7 months ago

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

ALDX ALEC BDTX

Oct 3, 2025, 9:05 AM EDT - 7 months ago

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Aug 7, 2025, 4:41 PM EDT - 9 months ago

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 4:45 PM EDT - 9 months ago

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

May 12, 2025, 4:15 PM EDT - 1 year ago

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 4:01 PM EDT - 1 year ago

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

May 1, 2025, 5:04 PM EDT - 1 year ago

Coherus to Participate in Upcoming Investor Conferences

Apr 28, 2025, 10:10 AM EDT - 1 year ago

Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 10, 2025, 4:12 PM EDT - 1 year ago

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

Mar 3, 2025, 8:30 AM EST - 1 year ago

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

Feb 24, 2025, 9:08 AM EST - 1 year ago

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

Dec 18, 2024, 8:30 AM EST - 1 year ago

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Dec 3, 2024, 9:34 AM EST - 1 year ago

Why Is Coherus BioSciences Stock Trading Higher On Tuesday?

Nov 27, 2024, 4:01 PM EST - 1 year ago

Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

Nov 6, 2024, 4:01 PM EST - 1 year ago

Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 30, 2024, 4:20 PM EDT - 1 year ago

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

Aug 1, 2024, 9:00 AM EDT - 1 year ago

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

Jun 27, 2024, 8:26 AM EDT - 1 year ago

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

May 30, 2024, 9:00 AM EDT - 2 years ago

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

May 23, 2024, 5:51 PM EDT - 2 years ago

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23, 2024, 9:00 AM EDT - 2 years ago

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

May 9, 2024, 4:01 PM EDT - 2 years ago

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 7:30 AM EDT - 2 years ago

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

May 8, 2024, 9:00 AM EDT - 2 years ago

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer

May 1, 2024, 4:30 PM EDT - 2 years ago

Coherus to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 24, 2024, 10:02 AM EDT - 2 years ago

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 8, 2024, 8:30 AM EDT - 2 years ago

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

Mar 13, 2024, 4:01 PM EDT - 2 years ago

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

Mar 5, 2024, 4:01 PM EST - 2 years ago

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

Mar 4, 2024, 1:00 AM EST - 2 years ago

Coherus Completes Divestiture of Ophthalmology Franchise

Feb 23, 2024, 5:33 PM EST - 2 years ago

Coherus BioSciences Announces New Employment Inducement Grants

Feb 21, 2024, 8:30 AM EST - 2 years ago

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Feb 5, 2024, 8:00 AM EST - 2 years ago

Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP

Jan 22, 2024, 1:15 AM EST - 2 years ago

Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal

Jan 18, 2024, 4:05 PM EST - 2 years ago

Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium

Jan 4, 2024, 8:00 AM EST - 2 years ago

INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)

INO

Jack_Nicholson_Truth Apr. 24 at 9:29 PM

$CHRS another scam artist. Tell us more 30 years experience scammer. You have like one post every 6 months and clearly a scam account. Your choices are horrible so stop spreading your fud

0 · Reply

bioinsights Apr. 24 at 5:43 PM

2 · Reply

Grandgustav Apr. 24 at 2:38 PM

$CHRS

0 · Reply

cdlawton07 Apr. 24 at 12:43 PM

0 · Reply

bioinsights Apr. 24 at 12:23 PM

0 · Reply

calibran_de Apr. 23 at 8:16 PM

$CHRS https://www.tipranks.com/news/blurbs/oppenheimer-reaffirms-their-buy-rating-on-coherus-biosciences-chrs-blurbs-news?utm_source=edition.cnn.com&utm_medium=referral

0 · Reply

BigDaddyCapital Apr. 23 at 7:35 PM

$CHRS whether you like this or not it is partially true. Which is why sp has been like a zombie company

1 · Reply

AlbertoBurgio Apr. 23 at 6:59 PM

$CHRS thank you for posting, I was waiting for the Samishere pattern to form. Now the signal is on.

1 · Reply

Samishere Apr. 23 at 6:20 PM

$CHRS Yep Yep ..and Yep!

1 · Reply

cdlawton07 Apr. 23 at 5:25 PM

0 · Reply

Samishere Apr. 23 at 5:13 PM

$CHRS Where are the uber pump chumps Neofraud & Jackass hiding today? No Data ( as predicted) A bag of Phase 1 maybes And a mediocre Chinese PD-1 that cant be acquired without multiple strings attached ( Chinese strings to boot) Oh yeah, and a scumbag CEO & management GLTA!

1 · Reply

bioinsights Apr. 23 at 5:10 PM

$CHRS Small differences in MOA do not matter. What is important for the CHRS PD1 strategy is future clinical trials given the Tori data in China does not transfer easily to the US due to study design and patient population differences. This is where most China-only programs fail to translate to the US reulatory environment. Our FDA requires the following: Results must be generalizable to U.S. patients. Standard of care must match U.S. practice. Investigators and sites must be credible and inspectable. If not, FDA will require additional U.S. or multi-regional trials.

1 · Reply

whateverhappenedthere Apr. 23 at 5:09 PM

$CHRS I guess Denny embargoed any good news until after the option price reset 😂 May 28 expect some banger PRs I hope!

3 · Reply

cdlawton07 Apr. 23 at 2:38 PM

$CHRS If they are mechanistically equivalent; why does Tori outperform Pembro in patients with low PD-L1 status?

0 · Reply

Samishere Apr. 23 at 1:49 PM

$CHRS .75 cents here we come! This garbage is a shorts dream. Horrible bullshitting management Constant dilution Phase1 big fat maybes that get retail idiots excited One mediocre Chinese product they don’t even own By the why, Junshi can put the kabash on any acquisition involving Tori,, yea look it up! No ones buying a Chinese rental! .75 cents coming soon

0 · Reply

BigDaddyCapital Apr. 23 at 1:47 PM

$CHRS people dumping on no data. Big candles to start the day

1 · Reply

simonig1 Apr. 23 at 1:00 PM

$CHRS Forecast came up this morning: link: https://www.tipranks.com/stocks/chrs/forecast

0 · Reply

Thomas105 Apr. 23 at 12:47 PM

$CHRS new oppenheimer rating from today

1 · Reply

bioinsights Apr. 23 at 11:41 AM

$CHRS The US FDA will not accept chineses data from studies unles it follows FDA guidence. Having said that there is zero difference between the proudcts from an MOA /biologic activity perspective. Toripalimab and Pembrolizumab share the same MOA: both are IgG4 monoclonal antibodies that bind PD-1 on T cells, blocking PD-L1/PD-L2 interactions and restoring antitumor immune activity. Toripalimab binds a slightly different PD-1 epitope, but this does not meaningfully change function. Both avoid T-cell depletion and act by reactivating exhausted T cells. Overall, they are mechanistically equivalent, with differences driven by clinical positioning rather than biology.

4 · Reply

Samishere Apr. 23 at 1:13 AM

$CHRS It’s approved for one indication, Head & Neck,, wtf are talking about

1 · Reply

simonig1 Apr. 22 at 7:36 PM

$CHRS You're a good bullshitte artist Sam. What you call that "mediocre Chinese PD-1" is approved in cases where Keytruda is not (does NOT work)!!!

2 · Reply

Samishere Apr. 22 at 6:41 PM

$CHRS A good chunk of those 28 are small, single-center studies from China (e.g., "Toripalimab in rare salivary gland tumors" or "Small-scale study in bladder cancer"). These add to the bullshitte 28-count but don't typically impact the FDA's view or the stock's valuation. IE- old news. There’s only two worth mentioning , Phase 1b data involving Tagmokitug (CCR8) or Casdozokitug (IL-27), and well, Phase 1…, meaning YEARS away from anything! This 💩 company is nothing more than a distributer of a mediocre Chinese PD-1! Nothing more !

0 · Reply

Market Cap	90.31M
Revenue (ttm)	266.96M
Net Income (ttm)	28.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	10.68%
Debt to Equity Ratio	-0.20

Volume	1,822,400
Avg Vol	1,708,078
Day's Range	N/A - N/A
Shares Out	115.93M
Stochastic %K	30%
Beta	1.01
Analysts	Strong Sell
Price Target	$5.26